Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial

V Rantalaiho; J Martikainen; H Kautiainen

doi:10.1136/annrheumdis-2014-eular.3265

Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial

V Rantalaiho
, J Martikainen
, H Kautiainen

Research output: Other conference contribution › Abstract › Scientific

Original language	English
Pages	85
DOIs	https://doi.org/10.1136/annrheumdis-2014-eular.3265
Publication status	Published - 2014
Publication type	Not Eligible
Event	Annual European Congress of Rheumatology - Duration: 1 Jan 2014 → …

Conference

Conference	Annual European Congress of Rheumatology
Period	1/01/14 → …

Access to Document

10.1136/annrheumdis-2014-eular.3265

Cite this

@conference{6ec185d4d6a9401f978f188095593a2e,

title = "Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial",

author = "V Rantalaiho and J Martikainen and H Kautiainen",

year = "2014",

doi = "10.1136/annrheumdis-2014-eular.3265",

language = "English",

pages = "85",

note = "Annual European Congress of Rheumatology ; Conference date: 01-01-2014",

}

TY - CONF

T1 - Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial

AU - Rantalaiho, V

AU - Martikainen, J

AU - Kautiainen, H

PY - 2014

Y1 - 2014

U2 - 10.1136/annrheumdis-2014-eular.3265

DO - 10.1136/annrheumdis-2014-eular.3265

M3 - Abstract

SP - 85

T2 - Annual European Congress of Rheumatology

Y2 - 1 January 2014

ER -